Carotid endarterectomy: technical practices of surgeons participating in the GALA trial.

OBJECTIVE: Recent meta-analyses confirm an advantage to patch angioplasty during carotid endarterectomy (CEA) and suggest a benefit from routine shunting. GALA Trial (RCT: general [GA] versus local [LA] anaesthesia for CEA) collaborators (non-UK [European] and UK) were surveyed to assess current practice techniques. MATERIALS AND METHODS: Postal questionnaires determined: shunt usage, monitoring techniques dictating shunt deployment, criteria for patching and the influence of anaesthetic technique upon these decisions. RESULTS: 157/216 surgeons (73%) replied. For UK surgeons (n=76) performing GA CEA a shunt was always, never, or selectively used by 73.6%, 4.2% and 22.2% respectively. Figures for non-UK surgeons (n=77) were 20.8% (p<0.0001), 26% (p<0.0002) and 53.2% (p<0.0001). When shunting selectively, fewer UK surgeons relied on stump pressure (26.4% v 48.1%; p<0.0064) with TCD more widely used (38.9% v 11.7%; p<0.0001). Shunting criteria during LA CEA were the same for both groups (impaired awake-testing). Routine patching was commoner amongst UK surgeons (GA: 76.4% v 34.2%, p<0.0001; LA: 70.1% v 31.9%, p<0.0001). CONCLUSIONS: These results indicate that more UK surgeons have adopted current suggestions for improving CEA outcomes. Future analysis of unblinded GALA Trial data may provide further information about the impact of different policies for shunting and patching.

An overview of cytokine interactions in atherosclerosis and implications for peripheral arterial disease.

Over the last three decades, a surge in research into the inflammatory pathophysiology of atherosclerosis has highlighted an array of cytokines and other inflammatory mediators associated with underlying inflammatory burden. The ability to identify and simultaneously measure multiple cytokines in peripheral blood highlights their potential as biomarkers of atherosclerosis. This has prompted much research in vascular medicine to identify the ;at-risk' groups for atherostenotic or atheroaneurysmal disease. This review is compiled with similar intentions and aims to discern the relevant evidence for cytokine profiling in peripheral arterial disease (PAD), where such information is lacking, while providing a holistic overview of cytokine interactions in atherosclerosis. This is pertinent given that cytokine profiles from coronary artery disease and aortic aneurysm studies cannot be directly extrapolated to PAD due to differences in inflammatory environments that exist in these conditions. Whilst plaque morphology and blood rheology play an important role in the cardiac manifestations of atherosclerosis, tissue thrombogenecity is very important in PAD. Further, cytokines act in concert rather than in isolation in a disease process, and no single cytokine in a cross-sectional model is able to serve as an absolute screening marker. Thus, it is essential to understand the regulation of cytokine production in atherosclerosis prior to evaluating the viability and merits of a multimarker approach for clinical risk stratification in PAD.